PAVmed Operating Income vs Depreciation And Amortization Analysis
PAVM Stock | USD 0.85 0.0001 0.01% |
PAVmed financial indicator trend analysis is much more than just breaking down PAVmed Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PAVmed Inc is a good investment. Please check the relationship between PAVmed Operating Income and its Depreciation And Amortization accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Operating Income vs Depreciation And Amortization
Operating Income vs Depreciation And Amortization Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PAVmed Inc Operating Income account and Depreciation And Amortization. At this time, the significance of the direction appears to have pay attention.
The correlation between PAVmed's Operating Income and Depreciation And Amortization is -0.74. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of PAVmed Inc, assuming nothing else is changed. The correlation between historical values of PAVmed's Operating Income and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of PAVmed Inc are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Operating Income i.e., PAVmed's Operating Income and Depreciation And Amortization go up and down completely randomly.
Correlation Coefficient | -0.74 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Operating Income
Operating Income is the amount of profit realized from PAVmed Inc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of PAVmed Inc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most indicators from PAVmed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PAVmed Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, PAVmed's Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Issuance Of Capital Stock is likely to grow to about 29.4 M, while Enterprise Value Over EBITDA is likely to drop (0.82).
2023 | 2024 (projected) | Total Operating Expenses | 64.8M | 68.1M | Non Recurring | 236.9K | 210.6K |
PAVmed fundamental ratios Correlations
Click cells to compare fundamentals
PAVmed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PAVmed fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 7.2M | 19.8M | 87.0M | 54.0M | 33.1M | 23.6M | |
Other Current Liab | 1.4M | (15.0M) | 4.3M | 3.7M | 6.6M | 7.0M | |
Total Current Liabilities | 11.9M | 20.0M | 7.6M | 41.2M | 54.2M | 56.9M | |
Total Stockholder Equity | (3.8M) | 1.9M | 61.7M | (9.7M) | (53.8M) | (51.1M) | |
Net Tangible Assets | (6.1M) | (641K) | 57.2M | (15.8M) | (18.2M) | (17.3M) | |
Net Debt | 1.9M | (2.3M) | (77.3M) | (3.1M) | 29.1M | 30.5M | |
Retained Earnings | (53.7M) | (88.3M) | (138.9M) | (228.2M) | (294.4M) | (279.7M) | |
Accounts Payable | 2.4M | 3.0M | 3.3M | 2.7M | 1.8M | 1.9M | |
Cash | 6.2M | 17.3M | 77.3M | 39.7M | 19.6M | 18.9M | |
Cash And Short Term Investments | 6.2M | 17.3M | 77.3M | 39.7M | 19.6M | 18.9M | |
Common Stock Total Equity | 27.1K | 40.5K | 64K | 86K | 98.9K | 103.8K | |
Common Stock Shares Outstanding | 2.0M | 3.2M | 5.2M | 5.9M | 7.2M | 6.9M | |
Liabilities And Stockholders Equity | 7.2M | 19.8M | 87.0M | 54.0M | 33.1M | 23.6M | |
Capital Surpluse | 32.6M | 47.6M | 87.6M | 198.1M | 227.8M | 239.2M | |
Other Current Assets | 328.3B | 1.7M | 5.2M | 3.9M | 3.8M | 3.6M | |
Other Stockholder Equity | 47.6M | 87.6M | 198.1M | 215.9M | 237.6M | 249.5M | |
Total Liab | 11.9M | 20.3M | 7.6M | 43.0M | 57.1M | 60.0M | |
Total Current Assets | 6.5M | 18.9M | 82.6M | 43.9M | 24.5M | 20.8M | |
Common Stock | 40.5K | 64K | 86K | 95K | 9K | 8.6K | |
Non Current Assets Total | 692.9K | 837K | 4.3M | 10.1M | 8.6M | 9.1M | |
Non Currrent Assets Other | 692.9K | 755K | 725K | 1.1M | 1.1M | 614.4K | |
Other Assets | 693K | 837K | 725K | 1.1M | 1.0 | 0.95 | |
Non Current Liabilities Total | 10.5M | 300K | 4.3B | 1.8M | 3.0M | 2.8M | |
Noncontrolling Interest In Consolidated Entity | (161.5K) | (814.3K) | (2.4M) | 17.8M | 20.4M | 21.4M | |
Retained Earnings Total Equity | (37.0M) | (53.7M) | (88.3M) | (138.9M) | (125.0M) | (118.8M) | |
Short Term Investments | 34K | 262K | 2.0M | 3.0M | 2.7M | 2.8M | |
Preferred Stock Total Equity | 2.0M | 2.3M | 2.5M | 2.4M | 2.8M | 1.9M | |
Property Plant Equipment | 692.9K | 82K | 1.6M | 5.5M | 6.3M | 6.6M | |
Short Long Term Debt Total | 7.9M | 8.1M | 15.0M | 36.6M | 48.7M | 51.2M | |
Net Invested Capital | 2.0M | 14.3M | 59.2M | 21.3M | (12.6M) | (12.0M) | |
Short Long Term Debt | 7.9M | 8.1M | 14.7M | 33.7M | 44.2M | 46.4M | |
Net Working Capital | (5.3M) | (1.0M) | 75.1M | 2.7M | (29.7M) | (28.2M) | |
Short Term Debt | 7.9M | 8.1M | 15.0M | 34.8M | 45.8M | 48.1M | |
Capital Stock | 2.3M | 2.6M | 2.5M | 2.8M | 3.0M | 2.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PAVmed. If investors know PAVmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PAVmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Revenue Per Share 0.459 | Quarterly Revenue Growth 4.898 | Return On Assets (0.80) | Return On Equity (13.58) |
The market value of PAVmed Inc is measured differently than its book value, which is the value of PAVmed that is recorded on the company's balance sheet. Investors also form their own opinion of PAVmed's value that differs from its market value or its book value, called intrinsic value, which is PAVmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PAVmed's market value can be influenced by many factors that don't directly affect PAVmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PAVmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if PAVmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PAVmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.